Drugmaker Eli Lilly Reports Fourth-Quarter Earnings
Increasing demand for Eli Lilly's (NYSE: LLY) diabetes and oncology treatments helped push its fourth-quarter 2019 revenue up 8.5% year-over-year to $6.1 billion. The company also reported GAAP earnings per share (EPS) of $1.64, up 49.1% year-over-year, due to expanding margins. Those results exceeded industry watchers' consensus revenue and EPS estimates for $5.92 billion and $1.54, respectively.
IMAGE SOURCE: GETTY IMAGES.
As one of the largest manufacturers of medications used to control blood sugar levels, Eli Lilly benefited last quarter from increased sales of diabetes drugs Trulicity, Basaglar, and Jardiance.
Source Fool.com
